Role of hsnf5/BAF47 Loss in Human Cancer Development

hsnf5/BAF47 缺失在人类癌症发展中的作用

基本信息

  • 批准号:
    7585343
  • 负责人:
  • 金额:
    $ 26.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-03-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The identification of tumor suppressor genes has led to new insights into the mechanisms of human cancer development. The normal functions of these genes often lie in the control of gene expression, especially in the realm of cell cycle control and cellular differentiation. Several recent studies have implicated aberrant activity of chromatin remodeling complexes in the development of human cancer. Mutations in the INI1/SNF5/BAF47 gene, a component of the SWI/SNF chromatin remodeling complex, occur in virtually all malignant rhabdoid tumors (MRTs). The SWI/SNF complex acts as a global transcriptional activator that alters nucleosome positioning on DNA via an energy-dependent mechanism. During the previous funding period, we have determined that loss of SNF5 expression affects cell cycle regulation in all MRT cell lines. We also developed 2 genetically engineered mouse (GEM) models for MRT development where loss of expression of the pRb family members or decreased expression of p53 accelerates the appearance of spinal cord MRTs. Importantly, our preliminary studies have now put forward 4 candidate genes suspected of supporting SNF5 tumor suppressor action. Based on these results, we hypothesize that loss of SNF5 expression can lead to MRT development through disruption of neural differentiation. To test this hypothesis, we propose 3 specific aims. In the first specific aim, we will characterize novel targets of SNF5 in human MRT cell lines using Taq-Man(R) assays, Western blotting and ChIPs, determine their role in MRT oncogenesis using cell culture models and assess the effects of SNF5 loss on chromatin structure and modifications in their promoter regions. The second specific aim will identify downstream targets of SNF5 associated with MRT development using a combination of high-throughput DNA sequencing approach (ChIP-seq) and gene expression array analyses. In the third specific aim, we will determine the role of Snf5 inactivation in neural cell development and malignant rhabdoid tumorigenesis using novel genetically engineered mouse models, neurosphere cultures and a comparison of mouse spinal cord MRTs with human MRTs of the central nervous system. The dissection of the role SNF5 plays in MRT development will broaden our understanding of its normal biological and biochemical activities, provide new insights into the function of the SWI/SNF complex in cell cycle regulation and normal development and identify new avenues of treatment for this highly aggressive tumor. PUBLIC HEALTH RELEVANCE: Tumor suppressor genes are turned off in many human cancers and are often responsible for the familial forms of this disease. We are studying one of these genes called INI1/SNF5/BAF47 that plays an important role in the development of an aggressive childhood cancer of the kidney, brain and soft tissues called malignant rhabdoid tumor (MRT). Our previous studies have suggested that the loss of this gene before or early after birth may interfere with normal nervous system development leading to the appearance of MRT in children. This current grant will carry out further studies to test this hypothesis using MRT cells grown in culture, DNA and protein from these cells and genetically-modified mice that will lose INI1/SNF5/BAF47 expression in nervous tissues. By doing these studies, we will broaden our understanding of its normal biological and biochemical activities and identify new avenues of treatment for this highly aggressive tumor.
描述(由申请人提供):肿瘤抑制基因的鉴定导致了对人类癌症发展机制的新见解。这些基因的正常功能通常在于控制基因表达,特别是在细胞周期控制和细胞分化领域。最近的几项研究表明,染色质重塑复合物的异常活性与人类癌症的发生有关。INI 1/SNF 5/BAF 47基因突变是SWI/SNF染色质重塑复合物的一个组成部分,几乎发生在所有恶性横纹肌样瘤(MRT)中。SWI/SNF复合物作为一种全局转录激活因子,通过能量依赖机制改变核小体在DNA上的定位。在之前的资助期间,我们已经确定SNF 5表达的缺失会影响所有MRT细胞系的细胞周期调控。我们还开发了2种用于MRT发展的基因工程小鼠(GEM)模型,其中pRb家族成员表达缺失或p53表达减少会加速脊髓MRT的出现。重要的是,我们的初步研究现在已经提出了4个候选基因,怀疑支持SNF 5肿瘤抑制作用。基于这些结果,我们假设SNF 5表达的缺失可以通过破坏神经分化导致MRT的发展。为了验证这一假设,我们提出了三个具体目标。在第一个具体目标中,我们将使用Taq-Man(R)分析,蛋白质印迹和ChIP来表征人类MRT细胞系中SNF 5的新靶点,使用细胞培养模型来确定它们在MRT肿瘤发生中的作用,并评估SNF 5缺失对染色质结构及其启动子区域修饰的影响。第二个具体目标将使用高通量DNA测序方法(ChIP-seq)和基因表达阵列分析的组合来确定与MRT发展相关的SNF 5下游靶点。在第三个具体目标,我们将确定Snf 5失活的作用,在神经细胞发育和恶性横纹肌样瘤的发生,使用新的基因工程小鼠模型,神经球文化和比较小鼠脊髓MRT与人类MRT的中枢神经系统。SNF 5在MRT发展中所起作用的解剖将拓宽我们对其正常生物学和生化活性的理解,为SWI/SNF复合物在细胞周期调节和正常发育中的功能提供新的见解,并确定治疗这种高度侵袭性肿瘤的新途径。公共卫生相关性:肿瘤抑制基因在许多人类癌症中被关闭,并且通常是这种疾病的家族形式的原因。我们正在研究其中一种名为INI 1/SNF 5/BAF 47的基因,它在一种名为恶性横纹肌样瘤(MRT)的侵袭性儿童肾癌、脑癌和软组织癌的发展中起着重要作用。我们以前的研究表明,出生前或出生后早期这种基因的丢失可能会干扰正常的神经系统发育,导致儿童出现MRT。目前的资助将进行进一步的研究,以测试这一假设,使用在培养中生长的MRT细胞,来自这些细胞的DNA和蛋白质,以及在神经组织中失去INI 1/SNF 5/BAF 47表达的转基因小鼠。通过这些研究,我们将扩大我们对其正常生物学和生化活性的理解,并确定治疗这种高度侵袭性肿瘤的新途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bernard E. Weissman其他文献

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type
超级增强子与雷公藤甲素在卵巢高钙血症型小细胞癌中的疗效
  • DOI:
    10.1016/j.isci.2025.111770
  • 发表时间:
    2025-02-21
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    Jessica D. Lang;William Selleck;Shawn Striker;Nicolle A. Hipschman;Rochelle Kofman;Anthony N. Karnezis;Felix K.F. Kommoss;Friedrich Kommoss;Jae Rim Wendt;Salvatore J. Facista;William P.D. Hendricks;Krystal A. Orlando;Patrick Pirrotte;Elizabeth A. Raupach;Victoria L. Zismann;Yemin Wang;David G. Huntsman;Bernard E. Weissman;Jeffrey M. Trent
  • 通讯作者:
    Jeffrey M. Trent
Mutant Nrf2supE79Q/sup enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors
突变的NRF2SUPE79Q/SUP增强了致癌性Ras角质形成细胞和皮肤肿瘤的促进和进展
  • DOI:
    10.1016/j.redox.2024.103261
  • 发表时间:
    2024-09-01
  • 期刊:
  • 影响因子:
    11.900
  • 作者:
    John G. Witherspoon;Jonathan R. Hall;Dereje Jima;Hannah M. Atkins;Nathan T. Wamsley;Michael B. Major;Bernard E. Weissman;Robert C. Smart
  • 通讯作者:
    Robert C. Smart
SNF5/INI1 Deficiency Destabilizes the SWI/SNF Complex During Malignant Rhabdoid Tumor Development
  • DOI:
    10.1016/j.cancergen.2014.09.007
  • 发表时间:
    2014-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Yasumichi Kuwahara;Darmood Wei;Shujie Song;Courtney Cannon;Donastas Sakellariou-Thompson;Michael Emanuele;Hajime Hosoi;Bernard E. Weissman
  • 通讯作者:
    Bernard E. Weissman

Bernard E. Weissman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bernard E. Weissman', 18)}}的其他基金

Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    9977976
  • 财政年份:
    2017
  • 资助金额:
    $ 26.9万
  • 项目类别:
Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    10240322
  • 财政年份:
    2017
  • 资助金额:
    $ 26.9万
  • 项目类别:
Cancer Epigenetics Training Grant
癌症表观遗传学培训补助金
  • 批准号:
    9756152
  • 财政年份:
    2017
  • 资助金额:
    $ 26.9万
  • 项目类别:
Animal Models Core Facility
动物模型核心设施
  • 批准号:
    8340285
  • 财政年份:
    2011
  • 资助金额:
    $ 26.9万
  • 项目类别:
Role of hsnf5/BAF47 Loss in Human Cancer Development
hsnf5/BAF47 缺失在人类癌症发展中的作用
  • 批准号:
    8322896
  • 财政年份:
    2011
  • 资助金额:
    $ 26.9万
  • 项目类别:
SWI/SNF complex loss facilitates gene silencing during NSCLC development
SWI/SNF 复合物丢失促进 NSCLC 发展过程中的基因沉默
  • 批准号:
    7635080
  • 财政年份:
    2009
  • 资助金额:
    $ 26.9万
  • 项目类别:
CORE--ANIMAL PROCEDURES
核心——动物程序
  • 批准号:
    7100664
  • 财政年份:
    2004
  • 资助金额:
    $ 26.9万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    6681590
  • 财政年份:
    2003
  • 资助金额:
    $ 26.9万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    6790490
  • 财政年份:
    2003
  • 资助金额:
    $ 26.9万
  • 项目类别:
SWI/SNF Chromatin Remodeling Loss and Human Cancer
SWI/SNF 染色质重塑损失与人类癌症
  • 批准号:
    7098021
  • 财政年份:
    2003
  • 资助金额:
    $ 26.9万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 26.9万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 26.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 26.9万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 26.9万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了